Click here for a PDF copy of Hexima’s Interim Financial Report for the 6 months ended 31 December 2017.
- Hexima Limited – Interim Financial Report for the 6 Months ended 31 December 2017
- Hexima doses first patient in phase 1/2a trial of HXP124 as a novel topical treatment for fungal nail infections
- Recruiting patients for fungal nail study
- VIDEO: CSO Marilyn Anderson interviewed by the AAS.
- Hexima AGM 2017 – Presentations and Results